441 results on '"Prajapati, Vimal"'
Search Results
2. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis
3. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
4. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
5. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
6. FLUTAX Staining of Cilliates
7. DNA Isolation from Single Ciliate Isolate
8. Preparation and characterization of slow-release fertilizers loaded guar gum-g-poly methylmethacrylate-cl-polylactic acid (Gg-g-PMMA-cl-PLA) hydrogel and its effect on wheat growth
9. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
10. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
11. The burden of palmoplantar pustulosis: A Canadian population-based study of inpatient care, emergency departments, and outpatient clinics
12. The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics
13. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
14. Impact of oxy-hydrogen enriched gasoline on petrol engine performance and emissions
15. Metabolic Engineering Approach for Advanced Microbial Fuel Production Using Escherichia coli
16. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
17. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
18. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
19. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
20. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
21. Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line
22. Production, statistical optimization, and functional characterization of alkali stable pectate lyase of Paenibacillus lactis PKC5 for use in juice clarification
23. Halozymes: sources, catalytic mechanisms, and potential applications in industries
24. Considerations for defining and diagnosing generalized pustular psoriasis.
25. Kitchen waste for economical amylase production using Bacillus amyloliquefaciens KCP2
26. Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis
27. 528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)
28. Draft Genome Analysis of Acinetobacter indicus Strain UBT1, an Efficient Lipase and Biosurfactant Producer
29. Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review.
30. Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.
31. Management of pediatric plaque psoriasis using biologics
32. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
33. Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review
34. Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
35. Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study
36. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
37. Synthesis and performance evaluation of vegetable oil based wood finish polyurethane coating
38. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
39. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab
40. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
41. Use of Janus kinase inhibitors for granulomatous dermatoses: A systematic review
42. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: A multicenter retrospective study
43. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective
44. Optimization of organic solvent-tolerant lipase production by Acinetobacter sp. UBT1 using deoiled castor seed cake
45. Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis who recently failed guselkumab: a multicentre retrospective study of switching within the interleukin-23 inhibitor class
46. Optimization and characterization of PHA from isolate Pannonibacter phragmitetus ERC8 using glycerol waste
47. Efficacy and Safety of Upadacitinib Treatment in Adolescents with Moderate-to-Severe Atopic Dermatitis:Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
48. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab.
49. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis
50. Management of adult generalized pustular psoriasis using biologics: A systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.